Hench Larry L
Department of Materials and Tissue Engineering and Regenerative Medicine Centre, Imperial College London, Prince Consort Road, London, SW7 2AZ.
J Mater Sci Mater Med. 2006 Nov;17(11):967-78. doi: 10.1007/s10856-006-0432-z. Epub 2006 Nov 22.
Historically the function of biomaterials has been to replace diseased or damaged tissues. First generation biomaterials were selected to be as bio-inert as possible and thereby minimize formation of scar tissue at the interface with host tissues. Bioactive glasses were discovered in 1969 and provided for the first time an alternative; second generation, interfacial bonding of an implant with host tissues. Tissue regeneration and repair using the gene activation properties of Bioglass provide a third generation of biomaterials. This article reviews the 40 year history of the development of bioactive glasses, with emphasis on the first composition, 45S5 Bioglass, that has been in clinical use since 1985. The steps of discovery, characterization, in vivo and in vitro evaluation, clinical studies and product development are summarized along with the technology transfer processes.
从历史角度来看,生物材料的功能一直是替代患病或受损组织。第一代生物材料被选择为尽可能具有生物惰性,从而使与宿主组织界面处的瘢痕组织形成最小化。生物活性玻璃于1969年被发现,首次提供了一种替代方案;第二代是植入物与宿主组织的界面结合。利用生物玻璃的基因激活特性进行组织再生和修复提供了第三代生物材料。本文回顾了生物活性玻璃40年的发展历程,重点介绍了自1985年以来一直在临床使用的第一种成分45S5生物玻璃。总结了发现、表征、体内和体外评估、临床研究及产品开发的步骤以及技术转移过程。